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Summary
Background—Twenty-five percent of new anti-factor VIII (FVIII) antibodies (inhibitors) that
complicate hemophilia A occur in those with mild and moderate disease. Although intensive FVIII
treatment has long been considered a risk factor for inhibitor development in those with non-
severe disease, its strength of association and the influence of other factors have remained
undefined.
Objective—To evaluate risk factors for inhibitor development in patients with non-severe
hemophilia A.
Methods—Information on clinical and demographic variables and FVIII genotype was collected
on 36 subjects with mild or moderate hemophilia A and an inhibitor and 62 controls also with mild
or moderate hemophilia A but without an inhibitor.
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Results—Treatment with FVIII for six or more consecutive days during the prior year was more
strongly associated with inhibitor development in those ≥ 30 years of age compared with those <
30 years of age [adjusted odds ratio (OR) 12.62; 95% confidence interval (CI), 2.76–57.81 vs. OR
2.54; 95% CI, 0.61–10.68]. Having previously received < 50 days of FVIII was also not
statistically associated with inhibitor development on univariate or multivariate analysis.
Conclusions—These findings suggest that inhibitor development in mild and moderate
hemophilia A varies with age, but does not vary significantly with lifetime FVIII exposure days:




Although persons with severe hemophilia A [factor VIII (FVIII) activity < 1%] are at
greatest risk of developing an anti-FVIII antibody (inhibitor), up to 25% of new inhibitors
develop in patients with non-severe disease (FVIII activity 1–40%) [1]. Most of our
knowledge of risk factors for inhibitor development in those with non-severe hemophilia A
has come from uncontrolled observations or single institutional studies. These studies have
reported an association between intensive FVIII treatment and inhibitor formation. The
influence of factors such as age, FVIII genotype, number of lifetime FVIII exposure days
and race on inhibitor formation are less well understood in this population. The largest
reported case series in non-severe hemophilia A included 26 subjects of whom 16 (61.5%)
developed an inhibitor after intensive FVIII replacement therapy for surgery, trauma or
muscle bleeding [2]. In a recently reported longitudinal observational cohort study from a
single institution, receiving intensive FVIII treatment for the first time while undergoing
surgery carried a relative risk (RR) of inhibitor formation of 186 [95% confidence interval
(CI), 25–1403] [3].
The most frequently reported FVIII gene (F8) missense mutation associated with inhibitors
in non-severe hemophilia A is R593C [2,4]. Other commonly reported F8 missense
mutations include W2105C [5], R2150H [6] and W2229C [2]. Overall, F8 missense
mutations reported in association with inhibitors in non-severe hemophilia A have clustered
in one of three regions, leading some to postulate that mutations within certain sequences in
the A2 and A3 domains and near the junction of the C1 and C2 domains are more
immunogenic [2,7,8]. Only one study has evaluated the association of the FVIII genotype
with inhibitor formation in persons with non-severe hemophilia A [3]. Although the
previous study found the R593C mutation to be associated with inhibitor formation [relative
risk (RR) 10, 95% confidence interval (CI) 0.9–119], the population studied was enriched
with this mutation (38% of subjects).
The present study was undertaken in a diverse United States population to further evaluate
the association of intensive FVIII treatment and inhibitor formation in non-severe
hemophilia A and to identify additional risk factors for inhibitor formation, including the
FVIII genotype.
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This study, a case–control design, was approved by Institutional Review Boards at all
participating sites. Subjects were enrolled during an 18-month period beginning July 2007
and ending December 2008.
Case selection—Cases were defined as individuals with mild or moderate hemophilia A
(FVIII 1–40%) based on local FVIII testing and a history of either two inhibitor titers ≥ 1
BU mL–1 or one such inhibitor titer followed by the initiation of immune tolerance. As a
first step in case identification, 4653 males with non-severe hemophilia A that comprise the
Universal Data Collection (UDC) data set compiled by the Division of Blood Disorders of
the Centers for Disease Control and Prevention (CDC) [9] were screened for a history of one
elevated inhibitor titer. In order to initially be inclusive, only one positive inhibitor titer was
used as screening criteria. From this screen, 110 males with mild or moderate hemophilia A
were identified at 58 hemophilia treatment centers (HTCs) (Fig. 1). All HTCs with a
potential case subject were contacted to determine if the subject met inclusion criteria as a
true case and, if so, the HTC was invited to participate in the study. Of the 110 potential
cases initially identified on screening, 30 individuals at 24 HTCs were verified to meet the
case definition. Of the 24 HTCs with cases, 16 participated and enrolled 13 of the cases
identified in the initial screen. After reviewing their own patient records, which included
patients who developed an inhibitor prior to the start of UDC data collection in 1998 and
patients not enrolled in the UDC project, the 16 participating HTCs identified and enrolled
an additional 30 cases. The 13 case subjects originally identified from the UDC cohort and
the additional 30 subjects identified by participating centers comprised the 43 enrolled case
subjects. Of the potential case subjects not included in the study, three were verified by
participating HTCs, but were not enrolled; 14 were verified to meet the inclusion criteria,
but the HTC declined to participate; 66 did not meet the study inclusion criteria because they
had severe disease, did not have an inhibitor or the inhibitor titer was ≥ 1 BU mL–1 on only
one occasion without initiation of immune tolerance; and 14 could not be verified because of
a lack of response to queries. Information on race and baseline FVIII levels was available on
the 17 subjects that were verified to meet inclusion criteria, but were not enrolled.
Control selection—Each participating center was asked to enroll two control subjects for
each case that the center enrolled in the study. Only males with mild or moderate hemophilia
A (FVIII 1–40%) with prior exposure to FVIII but no history of an inhibitor were eligible to
participate as controls. Any prior exposure to FVIII was used as an inclusion criterion for
control subjects to include only those that would be considered at risk for inhibitor
development. To ensure that only truly inhibitor negative controls were included, only
patients with previous inhibitor titers < 0.6 BU mL–1 were eligible. All control subjects were
confirmed to have an inhibitor titer of < 0.6 BU mL–1 by testing at the CDC Molecular and
Hemostasis Laboratory using blood samples collected at enrollment. Using these criteria, 66
control subjects were enrolled (1.5 control subjects per case subject).
Data collection
After written informed consent was obtained, staff at HTCs completed a standard data
collection form for each case and control subject. The primary exposure of interest was
intensive FVIII treatment, defined as six or more consecutive days of FVIII replacement.
Data were collected on intensive FVIII treatment during the year preceding inhibitor
development for cases and during the year preceding enrollment for controls. Where
possible, information was based on medical record review, but if not available, patient recall
was employed. Other data collected included the following: self-identified race (Black or
KEMPTON et al. Page 3













African American, White, Asian or other); ethnicity (Hispanic or non-Hispanic); family
history of hemophilia and inhibitor; age at first factor infusion; HIV and hepatitis C antibody
(positive, negative and unknown); the type of FVIII products used; lifetime total number of
FVIII exposure days prior to inhibitor detection in cases or prior to enrollment in controls;
and FVIII genotype if known. In those that received intensive FVIII treatment, additional
data were collected as follows: method of FVIII delivery (bolus injection only or any period
of continuous infusion); highest daily dose; duration of daily FVIII treatment; indication for
treatment (joint bleed – spontaneous or traumatic, muscle bleed – spontaneous or traumatic,
bone fracture, surgery, intracranial hemorrhage or other); type of FVIII product used during
the intensive treatment; duration of intensive FVIII treatment and if infection (positive
culture or treatment with antibiotics) complicated the period of intensive FVIII treatment.
Laboratory materials and methods
Blood was collected via venipuncture into two 4.5-mL vacuumsealed tubes containing 3.2%
sodium citrate. Platelet-poor plasma was obtained by centrifugation. Red cells and buffy
coat were collected for DNA extraction. Samples were either stored at 2–8 °C and shipped
to the Molecular and Hemostasis Laboratory at the CDC within 24 h or stored at –70 °C
until shipment after 24 h.
Inhibitor titers were measured on control subject samples at CDC by a modification of the
Nijmegen–Bethesda assay [10]. An inhibitor titer ≥ 0.6 BU mL–1 was considered positive.
FVIII genotyping was performed by the Molecular and Hemostasis Laboratory at the CDC
except when historical FVIII genotype data were available (historical FVIII genotype was
used in three subjects). All exons, intron–exon junction regions and the 3′ untranslated
regions of F8 were sequenced in both directions by automated sequencer. The Variant-
SEQr™ protocol was used for resequencing on a 3730 DNA Analyzer from Applied
Biosystems (Carlsbad, CA, USA). The PCR primers and M13 sequencing primers are
described at http://www.ncbi.nlm.nih.gov/sites/entrez?db=probe with a few modifications to
the PCR primers to enhance throughput and reproducibility. Data were analyzed with
SeqScape® (Applied Biosystems). Inversions of intron 22 and intron 1 in F8 were examined
by PCR [11]. Mutations were assigned Human Genome Variation Society (HGVS) names
for protein amino acid changes using a Mutalyzer sequence variation nomenclature checker
at http://www.humgen.nl/mutalyzer from reference sequences NM_000132.3 and
NP_000123.1.
Missense mutations were classified according to whether the mutation was within specific
regions of the A2 or A3 domains or C1/C2 domain (amino acids 535–663, 1854–2019 and
2020–2286, respectively)[8].
Data analysis
Distribution of characteristics was compared for cases and controls using the χ2 distribution.
For sparse data, Fisher's exact test was utilized to calculate P-values. Age and baseline FVIII
activity was compared between cases and controls using Student's t-test. The odds ratio
(OR) was calculated from a 2 × 2 table and 95% confidence intervals (CI) were calculated.
Statistical significance of the OR was assessed using the χ2-test. To adjust for confounding,
a stratified analysis was performed. When the OR was relatively constant between
subgroups, it was combined using the Mantel–Haenszel method to form an adjusted OR.
Confounding was considered present if the adjusted OR varied by 10% or greater from the
unadjusted OR. The presence of effect modification was assessed using the Breslow Day
test for heterogeneity. In addition to a stratified analysis, multivariate analysis was done
using unconditional logistic regression. Predictor variables were included if they were
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potential confounders, demonstrated effect modification in the stratified analysis, have been
associated with inhibitors in severe hemophilia A or were potentially independently
associated with the outcome, inhibitor formation. For univariate and multivariate analyzes
baseline FVIII level and patient age were made into categorical variables. Because of the
increased risk of inhibitor formation with low FVIII levels, baseline FVIII activity was
categorized into two groups, 1 to < 2% or ≥ 2%. Age was arbitrarily categorized into two
equal groups defined by the median age of study subjects, < 30 or ≥ 30 years. The statistical
significance of interaction terms in the multivariate model, further indication of effect
modification, was assessed using both the Wald test and likelihood ratio test (LRT).
The subgroup of cases and controls exposed to intensive FVIII treatment were analyzed.
Cases and controls were compared using Wilcoxon's rank sum test for continuous variables
or Fisher's exact test for categorical variables.
Twenty subjects (eight cases and 12 controls) comprised 10 pairs of related subjects (one
pair of twins, six pairs of brothers and three pairs of cousins). Related pairs were concordant
for the presence of an inhibitor in the pair of twins and one pair of brothers and concordant
for the absence of an inhibitor in four pairs of brothers. The remaining four pairs were
discordant. The possible influence of these related pairs on variance estimates was
investigated by assessing the variance of the parameter estimate for the association between
the outcome and predictor variables after performing 1000 simulations in which one
member of each of the 10 related pairs was selected at random for inclusion in the analysis.
Based on these analyzes, the influence of the related pairs on the variance was small
therefore all related pairs were kept in the study population. All analyzes were performed
using SAS version 9.2 (Cary, NC, USA).
Results
Although genotype was not included in the initial inclusion/exclusion criteria, several
subjects were demonstrated to have an intron-22 inversion. In order to prevent
misclassification, subjects with mutations previously reported to be associated only with
severe disease in the HAMSTeRS database (accessed June 2009) were excluded from the
analysis (four cases and two controls with intron-22 inversion, one case with nonsense
mutation R427Stop, one case with nonsense mutation W2046Stop, one case with deletion
exon 1 and one control with delA1194) [12]. In addition, one control subject was excluded
because a negative inhibitor titer at enrollment could not be verified by inhibitor testing at
the CDC. The remaining 36 cases and 62 controls had complete data and formed the study
population. All 62 control subjects included in the analysis had a negative inhibitor titer at
the time of enrollment [median inhibitor titer 0.1 BU mL–1 (range 0–0.3 BU mL–1)]. When
the potential cases that were verified, but not enrolled, were compared with enrolled cases,
there was no difference in FVIII levels. Among the enrolled case subjects, the inhibitor titer
became positive after the year 2000 in 24 case subjects (66%), during the 1990s in 10
subjects (27%), during the 1980s in one subject (2.8%) and during the 1970s in one subject
(2.8%). Four case subjects (11.1%) had started immune tolerance after only one positive
inhibitor titer. Seventy-five percent of case subjects had a maximum inhibitor titer > 5 BU
mL–1, including thre of the four that started immune tolerance after one positive titer.
Neither the mean age nor the baseline FVIII level was different between cases and controls
[31.0 years vs. 31.1 years (P = 0.94) and 7.6% vs. 8.1% (P = 0.73)]. The baseline and
exposure characteristics of cases and controls are shown in Tables 1 and 2. Cases were more
likely to have received intensive FVIII treatment compared with controls (P < 0.001).
Distributions of age, race, ethnicity, family history of an inhibitor, total number of FVIII
exposure days and type of product used were not different between case and control
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subjects. Of the 17 case subjects that were verified but not enrolled, 22% were of black race.
If these potential case subjects had been enrolled, the proportion of black case subjects
would have increased to 13.2% but the distribution of race amongst cases and controls
would remain similar (P = 0.54).
There was no association between inhibitor development and the presence of a missense
mutation grouped within specific regions of the A2, A3 or C1/C2 domain of F8 where
missense mutations have been previously reported to commonly occur (Table 2). In both
cases and controls the majority of missense mutations were in the A2 and A3 domains. The
missense mutation R593C was significantly more common in cases than controls (19.4% vs.
4.8%, P = 0.03). The missense mutation N1922S was found more commonly in cases
compared with controls (16.7% vs. 6.5%), but the difference was not statistically significant
(P = 0.16).
The univariate association between these characteristics and inhibitor formation is shown in
Table 3. Having received intensive FVIII treatment during the prior year was strongly
associated with inhibitor development (OR 4.64).
The association between intensive FVIII treatment and inhibitor formation was further
explored utilizing a stratified analysis. Age (< 30 years or ≥ 30 years) showed effect
modification on the association between intensive FVIII treatment and inhibitor formation
(Breslow-Day P = 0.03). The association between intensive FVIII treatment and inhibitor
formation was greater in those 30 years of age or older (OR 13.54) compared with those <
30 years of age (OR 1.55). After adjustment for other variables (white race, baseline FVIII
activity 1 to < 2%, < 50 lifetime days of FVIII exposure prior to inhibitor formation or
enrollment, < 5 years of age at first FVIII exposure and recombinant product use), no
confounding or effect modification was seen.
On multivariate analysis (Table 4), intensive FVIII treatment was strongly associated with
inhibitor development in those 30 years of age or older and not in those < 30 years of age
(test for interaction LRT P = 0.12 and Wald P = 0.13). FVIII activity of 1 to < 2%
demonstrated a trend toward a statistically significant association with inhibitor formation (P
= 0.06). The R593C missense mutation was no longer statistically significantly associated
with inhibitor formation. Having < 50 prior FVIII exposure days was also not statistically
significantly associated with inhibitor formation. None of the following variables were
associated with inhibitor formation and, therefore, were excluded in the final model: a
family history of inhibitor, having received a recombinant FVIII product, having received
FVIII for the first time prior to 5 years of age or the missense mutation N1922S. When the
analysis was limited to those with mild disease only (FVIII > 5%), the results were similar,
although the interaction between age and intensive exposure was stronger (age ≥ 30 years
OR 39.18 and age < 30 years OR 1.14; LRT for interaction P = 0.05).
On analysis of the subgroup of subjects (18 cases and 11 controls) who were exposed to
intensive FVIII treatment, the median age in cases was 42.5 years [interquartile range (IQR)
38 years] compared with 22 years (IQR 23 years) in controls (P = 0.23). The median
baseline FVIII activity was similar between cases and controls [4.5% (IQR 9%) vs. 5.0%
(IQR 6%) (P = 0.86)]. The median duration of treatment days was significantly longer in
cases compared with controls [14.5 days (IQR 9 days) vs. 10 days (IQR 6 days) (P = 0.03)].
Continuous infusion of FVIII was used during the period of intensive FVIII treatment in
18.2% of controls and 38.9% of cases (P = 0.41). Surgery was the indication for intensive
FVIII treatment in 77.8% of cases compared with 36.4% of controls (P = 0.05). Of the 18
subjects (14 cases and four controls) who had surgery as the indication for intensive FVIII
treatment, seven received FVIII by continuous infusion and 11 received FVIII by bolus
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injection only. Having surgery as the indication for intensive treatment was weakly
associated with receiving > 50 Units kg–1 day–1 of FVIII but was not associated with longer
duration of treatment (> 14 days) (P = 0.06 and 0.47, respectively). In those over 30 years of
age, surgery was more likely to be the indication for intensive FVIII treatment compared
with those < 30 years (P = 0.01). Of those that underwent surgery as the indication for
intensive treatment, 78.6% (11/14) were for orthopedic indications in those over 30 years of
age compared with 25.0% (1/4) in those < 30 years of age. Surgical events were complicated
by infection in two cases. Joint or muscle bleeding was the indication for intensive FVIII
treatment in four case subjects and five control subjects. In the two remaining control
subjects, the indication for intensive FVIII treatment was pneumonia requiring a chest tube
and pericarditis, respectively. Infection complicated periods of intensive FVIII treatment for
non-surgical indications in two controls. In those that developed an inhibitor after intensive
FVIII treatment, the inhibitor occurred within 12 weeks of intensive FVIII treatment in 94%
(17/18) of cases.
Discussion
Inhibitor formation in non-severe hemophilia A is a major complication, transforming a
manageable disease to one with substantial morbidity. Although much has been learned over
the past decade about risk factors for inhibitor formation in those with severe hemophilia A,
very little is known about risk factors for inhibitor formation in non-severe hemophilia A. In
addition to confirming that intensive exposure to FVIII is a risk factor for inhibitor
development, this is the first study to identify an interaction between age and intensive FVIII
treatment. This interaction was present even after adjustment for a lifetime exposure to
FVIII of < 50 days. Therefore, the impact of intensive treatment in adults does not appear to
be the result of either less FVIII exposure prior to adulthood nor because intensive FVIII
treatment is their first exposure to FVIII.
Intensive FVIII treatment occurred relatively equally in those < 30 years of age and in those
≥ 30 years of age (24% and 35%, respectively, P = 0.22), however, the indication for
intensive FVIII treatment in each age group was different. In those cases that were 30 years
of age and older, surgery was the indication for intensive FVIII treatment in 14 out of the 17
subjects with 78.6% of these surgeries for orthopedic indications. Both severe traumatic
bleeding and surgery require intensive FVIII treatment and have been hypothesized to
potentiate inhibitor development through signals that cause antigens to be perceived as
foreign and dangerous thereby promoting an antibody response [13]. If danger signals are
considered to be important for inhibitor development in mild and moderate hemophilia A,
then these results may indicate that in patients < 30 years of age there are mechanisms for
danger signals to occur that are unrelated to intensive FVIII treatment, such as infections or
immunizations. Alternatively, danger signals may be less pathophysiologically important for
inhibitor development in young persons with non-severe hemophilia A. Although the
present study is the first to report on the interaction between age and intensive FVIII
treatment, a similar pattern was seen in the cohort reported by Eckardht et al. [3]. In their
study, 5 out of the 10 subjects with an inhibitor were older than 30 years of age. Inhibitor
development was associated with intensive FVIII treatment in 100% of older subjects and
only 40% of younger subjects. In the present study inhibitor development was associated
with intensive FVIII treatment in 68% of older subjects and 29% of younger subjects.
Although we can speculate that the risk of inhibitor development associated with intensive
exposure may be strongly influenced by the indication for intensive treatment and the types
of surgeries performed in older patients (i.e. orthopedic surgery), it is clearly multifactorial
and this study was not designed to evaluate the independent effect of surgery or a specific
type of surgery.
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There have been previous reports of the R593C mutation and its association with inhibitor
formation in patients with mild hemophilia A [14]. Most recently, in a cohort of subjects
from the Netherlands, 8 out of 10 subjects with an inhibitor had the R593C mutation [3].
However, because this mutation was determined to be a founder effect it may have been
over-represented in this population. In our more diverse US population, the missense
mutation R593C was again associated with inhibitor development on univariate analysis but
not multivariate analysis. In the present study, the R593C mutation was seen in subjects
from five different states and only two of the ten subjects were known to be related. The
N1922S mutation was the second most common mutation seen. Outside of these two
specific missense mutations, there did not appear to be a location on the FVIII gene where
mutations clustered, as has been previously hypothesized [8].
It is remarkable that 41.7% of case subjects developed their inhibitor after more than 50
prior days of FVIII exposure (Table 1). In severe hemophilia A, inhibitors develop after a
median of 9–14 FVIII exposure days [15,16]. In the cohort study reported by Eckhardt et al.,
[3] the total cohort of 138 mild and moderate hemophiliacs was significantly less treated
than our population with a median of 10 FVIII exposure days (IQR 23 days). Accordingly,
the effect of more or < 50 prior FVIII exposure days on inhibitor development could not be
assessed. The present study cannot exclude any association between prior FVIII exposure
and risk of inhibitor development, as it is not adequately powered to detect weak
associations. However, it does not appear that the risk of inhibitor development is as
significantly different before and after 50 days of FVIII exposure in persons with mild and
moderate hemophilia A as it is in those with severe hemophilia A.
The subset analysis suggested that among those who received intensive FVIII treatment,
both surgery and longer durations of FVIII treatment were associated with inhibitor
formation. Continuous infusion as a method of delivery of intensive FVIII treatment was not
significantly associated with inhibitor development in the present study. Although a small
effect of continuous infusion cannot be excluded, the strength of the association is less than
that between surgery and inhibitor formation. This result is in contrast to the study by
Sharathkumar et al. [7] who reported that continuous infusion was associated with inhibitor
formation. Additionally, in the cohort study reported by Eckhart et al. continuous infusion
was significantly associated with inhibitor formation after adjusting for the R593C missense
mutation, receipt of ones first intensive FVIII treatment at the time of surgery and FVIII
product change (RR 13; 95% CI 1.9–86). The different results may be due in part to the
different study populations: our subjects were older when compared with those studied by
Sharathkumar et al. and had more prior FVIII treatment compared with those studied by
Eckhardt et al. In addition, we were limited to a very small subset of our population for
those analyzes and our findings should be considered preliminary.
There are several limitations of this study. First, the sample size is small leading to a lack of
power to detect weak associations. Second, the independent effect of surgery or continuous
infusion on inhibitor formation could not be evaluated because these variables were only
determined in subjects that received intensive FVIII treatment. Third, the inclusion of
related subjects could impair the ability to detect the independent influence of FVIII
genotype vs. other genetic modifiers. However, only one related-pair of subjects had the
N1922S and the R593C mutation, respectively. Family history of inhibitor was the only
variable that was influenced by the choice of which member of a related pair was included
in the analysis. As a result, the univariate association between family history of an inhibitor
and inhibitor formation could be inflated. As the multivariate model was not altered
significantly with the inclusion or exclusion of the variable family history of inhibitor, we
felt that inclusion of the related subjects without additional adjustment was appropriate.
Fourth, we enrolled subjects based on their reported FVIII activity but their inclusion was
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re-evaluated when several intron-22 inversions were detected. In order to have a cohort of
subjects that clearly represented non-severe hemophilia A, 10 subjects with the FVIII
genotype associated only with severe disease in the HAMSTeRS database were excluded
from the analysis [12]. However, when these 10 were included, the association with
intensive FVIII treatment was not substantially changed (OR, 4.29; 95% CI, 1.81–10.25).
Lastly, the number of FVIII exposure days in one-third of subjects was based predominantly
on patient interview and recall. However, the use of recall alone was equal amongst cases
and controls (33.3% and 35.5%, respectively) and the distribution of prior exposure days
was similar amongst those that used patient recall and those that did not regardless of case–
control status. Therefore, we do not believe that a significant source of bias was introduced
with the use of patient recall to estimate prior FVIII exposure days when complete medical
records or calendars were not available.
Overall, the present study has demonstrated that intensive FVIII treatment is strongly
associated with inhibitor development in patients with non-severe hemophilia A. The risk is
greatest in those 30 years of age or older. Importantly, the risk of inhibitor development does
not appear to be as significantly influenced by the number of prior FVIII exposure days as
seen in patients with severe disease. Further clinical investigation is needed to understand
the effect of age on the risk of inhibitor development associated with intensive FVIII
treatment, and what aspects surrounding intensive FVIII treatment promote inhibitor
formation. Specifically, it will be important to determine which factors exert the greatest
influence: (i) surgical indications and if so, what types of surgery, (ii) method of FVIII
delivery, (iii) dose of FVIII, or (iv) duration of FVIII treatment.
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Flow diagram of case subject enrollment. UDC, universal data collection; BU, Bethesda
Unit; HTC, hemophilia treatment center; ITI, immune tolerance induction.
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Table 1
Frequency of characteristics in groups
Cases n = 36 Controls n = 62
Characteristics N (%) N (%) Chi-square P-value
Intensive FVIII treatment 18 (50.0) 11 (17.7) 11.38 < 0.001
Age
    < 30 years 17 (47.2) 33 (52.4) 0.24 0.62
    30–60 years 13 (36.1) 24 (38.7)
    > 60 years 6 (16.7) 5 (8.1)
Race
    White 32 (88.9) 56 (90.3) 0.16 0.92
    Black 3 (8.3) 5 (8.1)
    Other 1 (2.6) 1 (16)
Hispanic ethnicity 2 (5.6) 8 (12.9) –
0.32
*




    1–< 2% 5 (13.9) 4 (6.4) 2.08 0.35
    2–5% 16 (44.4) 25 (38.7)
    > 5% 15 (41.7) 33 (53.2)
Age at first factor infusion
    ≤ 2 years 10 (27.8) 23 (37.1) 3.28 0.19
    3–10 years 11 (30.6) 24 (38.7)
    > 10 years 15 (42.7) 15 (24.2)
Prior FVIII exposure
    ≤ 20 days 6 (16.7) 15 (24.2) 5.75 0.12
    21–50 days 15 (41.7) 12 (19.4)
    51–100 days 5 (13.9) 13 (20.9)
    > 100 days 10 (27.8) 22 (34.5)
Product during prior year
    Plasma-derived 8 (22.9) 9 (14.5) 3.86 0.14
    Recombinant 25 (71.4) 41 (66.1)
    None 2 (5.7) 12 (19.4)
HIV
    Negative 32 (88.9) 58 (93.6) 0.66 0.72
    Positive 2 (5.6) 2 (3.2)
    Unknown 2 (5.6) 2 (3.2)
HCV
    Negative 21 (58.3) 38 (61.2) 2.51 0.29
    Positive 11 (30.6) 22 (35.4)
    Unknown 4 (11.1) 2 (3.2)
*
Fisher's exact test. FVIII, factor VIII; HIV, human immunodeficiency virus; HCV, Hepatitis C virus.
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Table 2
Frequency of factor VIII mutation in groups
Cases Controls
Characteristics N (%) N (%) Chi-square P-value
Type of fVIII mutation N = 36 N = 62
    Missense 32 (88.9) 53 (85.5) 5.12 0.16
    Deletion 2 (5.56) 0
    Splice site 1 (2.8) 5 (8.1)
    None detected 1 (2.78) 4 (6.45)
Missense mutations in regions previously linked to inhibitor N = 32 N = 53
    A2 (535–663) 8 (25.0) 10 (18.9) 1.23 0.75
    A3 (1854–2019) 8 (25.0) 10 (18.9)
    C1/C2 (2020–2286) 5 (15.6) 10 (18.9)
    None 11 (34.4) 23 (43.4)
Domain location of missense mutation
    A1 (1–372) 3 (9.4) 3 (5.66) 2.69 0.61
    A2 (373–740) 11 (34.4) 22 (42.5)
    A3 (1690–2019) 11 (34.4) 14 (25.4)
    C1 (2020–2172) 2 (6.3) 8 (15.1)
    C2 (2173–2332) 5 (15.6) 6 (11.3)
Specific missense mutations
    R593C 7 (19.4) 3 (4.9) –
0.03
*
    N1922S 6 (16.7) 4 (6.5) –
0.16
*
    R2150H 3 (8.3) 3 (4.9) –
0.67
*
    W2229C 0 1 (16) – –
*
Fisher's exact test. fVIII, factor VIII.
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Table 3
Univariate association of characteristics with inhibitor development
Characteristics Odds ratio 95% CI
Age < 30 years 0.78 0.35–1.79
Race: White 0.86 0.23–3.27
Baseline FVIII 1 to < 2% 2.34 0.59–9.34
Family history of inhibitor 3.50 0.95–12.93
< 50 Lifetime exposure days to FVIII 1.82 0.79–4.17
Intensive FVIII treatment 4.64 1.84–11.67
Recombinant product during the prior year
* 1.16 0.48–2.81
Age ≤ 5 years at first factor exposure 0.84 0.34–1.91
R593C missense mutation 4.75 1.14–19.71
N1922S missense mutation 2.90 0.78–11.07
*
Use of a recombinant product vs. the combination of plasma-derived and no product use. FVIII, factor VIII.
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Table 4
Multivariate analysis of subject characteristics and their association with inhibitor formation
Characteristics Parameter Estimate SE OR CI
Intensive FVIII treatment
      < 30 years of age 0.96 0.74 2.54 0.61–10.68
      ≥ 30 years of age 2.54 0.78 12.63 2.76–57.81
    < 50 previous days of FVIII 0.45 0.61 2.08 0.74–5.90
Baseline FVIII 1 to < 2% 1.59 0.85 4.91 0.92–25.95
R593C 1.25 0.85 3.49 0.66–18.41
White race 0.19 0.78 1.20 0.26–5.52
Hosmer and Lemeshow goodness-of-fit = 2.56, degrees of freedom (DF) = 6, P-value = 0.86. Likelihood ratio = 23.38, DF = 7, P-value = 0.002. –2
Log Likelihood = 128.88 for intercept only and 105.49 for intercept and covariates. FVIII, factor VIII. All variables are adjusted for all other
variables.
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